Navigation Links
Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
Date:12/19/2007

Avastin offers patients the chance to live twice as long without their

disease advancing

BASEL, Switzerland, Dec. 19 /PRNewswire/ -- Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced renal cell cancer (RCC) in combination with interferon (IFN), the current standard of care*. Kidney cancer, known as renal cell carcinoma (RCC) is a disease that kills over 100,000 people per year world-wide(1).

There are few early symptoms in kidney cancer which means that unfortunately the majority of patients are diagnosed with advanced disease, where current treatment options are limited. Kidney cancer is highly resistant to chemotherapy and radiotherapy, which are often key weapons against other cancer types(2).

The approval was based on data from the pivotal phase III AVOREN trial, which showed that patients with advanced RCC who received Avastin in combination with IFN lived nearly twice as long without their disease progressing ("progression free survival"), as those who received IFN alone.

"The results of the AVOREN study confirmed that Avastin is a safe, effective and well tolerated treatment option for patients with advanced renal cell cancer," said Professor Bernard Escudier, Head of the Immunotherapy and Innovative Therapy Unit, Institut Gustave-Roussy, Paris, France and Principal Investigator of the pivotal AVOREN study. "Avastin effectively doubles the time in which patients live without their disease getting worse, so this approval has the potential to change the treatment landscape for this disease, where treatment options are still limited."

Avastin Approval Status

Kidney cancer is the fourth cancer type in which Avastin has demonstrated positive survival benefits for patients. Data from the comprehensive Avastin cancer clinical development programme have resulted in approvals in advanced colorectal, breast, lung, and now kidney cancer:
-- February 2004 (US) and January 2005 (EU) - first-line treatment in

patients with metastatic colorectal cancer (CRC)

-- June 2006 (US) - second-line treatment in patients with metastatic CRC

-- October 2006 (US) - first-line treatment in patients with advanced non

small cell lung cancer (NSCLC)

-- March 2007 (EU) - first-line treatment in patients with metastatic

breast cancer

-- April 2007 (Japan) - treatment in patients with recurrent or advanced

CRC

-- August 2007 (EU) - first-line treatment in patients with advanced NSCLC

-- December 2007 (EU) - first-line treatment in patients with advanced RCC

About the AVOREN Study

The AVOREN study is a randomised, controlled, double-blind, phase III study that included 649 patients with advanced kidney cancer from 101 study sites across 18 countries. Study participants received treatment with either Avastin and IFN alpha-2a or placebo and IFN alpha-2a, the standard of care in patients with advanced kidney cancer.
The results of the AVOREN trial showed that by adding Avastin to IFN:

-- Progression free survival (PFS) was almost doubled from a median of 5.4

to 10.2 months

-- Tumour response was significantly increased from 12.8% with IFN alone

to 31.4% when Avastin was added

-- Dose-reduction of IFN did not appear to affect the efficacy of the

combination with Avastin (based on PFS event free rates over time, as

shown by a sub-group analysis)

The study also showed a trend towards improved overall survival; however, these data are still pending. No new or unexpected adverse events were observed.

An interim analysis of AVOREN was performed in December 2006 and the benefits provided by Avastin were so positive that the Drug Safety Monitoring Board recommended that the trial was unblinded and all patients were offered treatment with Avastin. The study demonstrated for the first time that Avastin benefits patients in combination with an immunotherapeutic, the class of drugs to which IFN belongs.

*The approval is for the use of Avastin in patients with advanced and/or metastatic RCC in combination with IFN.

References

1. Parkin DM, Bray F, Ferlay J and Pisani P. 2002. CA Cancer J Clin, 2005; 55: 74-108.

2. De Mulder, PHM. Ann Oncol, 2007; 18 (Supplement 9): ix98-ix102.


'/>"/>
SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
3. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
4. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
5. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Medpace Strengthens Presence in Central Europe
9. Kline Study: Better Brushing Habits Boost European Oral Care Sales
10. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
11. European Centre for Modern Drug Discovery Established in Hamburg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a leading ... (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. ... tables for its annual event, which will run from 3:00 p.m. - 8:30 ...
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads announces ... the secure online PatientCrossroads platform, has exceeded both its one-year and overall recruitment ... PROMPT study, which seeks to advance understanding of the hereditary risks for certain ...
(Date:2/10/2016)... ... , ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused on the discovery ... has been selected to present at the Cavendish Global Health Impact Forum taking place ... purpose of the Forum is to help family offices and foundations develop and implement ...
(Date:2/9/2016)... Feb. 9, 2016  Regenicin, Inc. (OTC Bulletin ... in the development and commercialization of regenerative cell ... and organs, recently reported the Company,s operating results ... of 2016. Lonza America , Inc. ... fiscal year in the process of consummating an ...
Breaking Biology Technology:
(Date:1/15/2016)... Rico , Jan. 15, 2016 Recent ... and small to find new ways to ensure data ... iOS and Android that ... on biometrics, transforming it into a hardware authorization token. ... users swipe their fingerprint on their KodeKey enabled device ...
(Date:1/13/2016)... 13, 2016 ... of the  "India Biometrics Authentication & ... (2015-2020)"  report to their offering.  ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the leading ... 10,000 retail locations, web and mobile, today announced ... million from existing investors. --> ... devoted to further innovate higi,s health platform – ... web portal – including expanding services and programs ...
Breaking Biology News(10 mins):